Day 2 agenda

Thursday, November 23

9.00-10.30

Clinical research and cannabis

Plenary session – Main hall, screening to halls 1 and 2

Evidence based medicine has its limitations. The existing gap between the research and the practice is evident and creates the obstacles for successful implementation of the research into the everyday practice. What are those barriers, and how can we overcome them?

Chair:
  • Allan Frankel (Greenbridge Medical Services)
Speakers:
  • Mark Ware (McGill Uni & IACM)
  • Philippe Lucas (Tilray)
  • + other participants based on abstracts selection

10.30-11.00             Coffee break

11.00-12.30

Cannabis and big pharma

Parallel session – main hall

For decades, pharmaceutical companies have mostly rejected even the idea of cannabis-based drugs into their portfolio. Introduction of cannabinoids might significantly harm their other income streams, mostly in the area of pain treatment – but is there enough potential for cannabis to be a new drug of choice for pharma? Some companies are already delving into cannabinoids.

Chair:
  • Ethan Russo (ICCI, Phytecs, Inc, formerly GW Pharmaceuticals)
Speakers:
  • Tomáš Zábranský (ResAd, ICCI)
  • Speaker’s slots open

Medical cannabis regulation in America, Australia, Israel

Parallel session – hall 1

Regional rules, implementation, outputs

Chair:
  • Mark Ware (McGill University and IACM)
  • Nicola Singleton (EMCDDA)
Speakers:
  • Representatives of the National Medical Cannabis Agencies of the EU Member States

Substitution of opioids in pain treatment with cannabinoids

Parallel session – hall 2

It has been proven with scientific studies, that cannabinoids can be a safe substitution for opioids. The benefits include not being exposed to the risk of addiction and also not bringing your body into life-threatening situations.

Chair:
  • Radovan Hřib (Chief Medical Doctor, Centre for Pain Treatment, St. Ann’s Faculty Hospital in Brno)
Speakers:
  • Philippe Lucas (Tilray)

12.30-13.30             Lunch

13.30-15.00

What the patients need?

Parallel session – main hall

… and what are they going to do with it? Most patients feel unsafe within the system, which does not protect their rights. There are millions of patients in the society today, that could potentially benefit from the health effects of cannabis – yet the medicine, that can help them live a quality life, is not available to them. In this session, we will also stress the importance of patient’s organisations.

Chair:
  • Steph Sherer (Americans for Safe Access, International Medical Cannabis Patients Consortium)
  • Hana Vagnerova (KOPAC, Czech association of cannabis patients)
Speakers:
  • Representatives of the National Medical Cannabis Agencies of the EU Member States

Cannabis/hemp-based nutrition

Parallel session – hall 1

Legal cannabis, known as hemp, is widely considered “a healthy food”. It has great nutritional values, and can be a good addition to a balanced diet, thus add to the therapeutic recovery treatments and prevention. We will discuss the legal status of hemp food products and hemp extract rich in CBD, the appropriate means of distribution, what are the basic norms that the hemp producer must adhere to, How to use hemp products as a dietary supplement, to help recovery from illness, to help with bodybuilding and reconvalescence.

Chair:
  • Hana Gabrielová (Hempoint – CEO and partner, also member of KOPAC board)
Speakers:
  • To be specified

Medical cannabis as an political issue in the Czech republic

Parallel session – hall 2

No one will do it for you. How the patients should approach the information they gather from various sources, and how shall they use them when communicating with their practicians and specialists.

Chair:
  • Tomáš Zábranský (ResAd, ICCI)
Speakers:
  • Filip Humplík, ODS (Civic democratic party)
  • Svatopluk Němeček, ČSSD (Social democrats) – or other option from the same party
  • Ivan Bartoš, Pirate party

+ other speakers from Czech political parties


15.00 – 15.30          Coffee break

15.30-17.00

Medical cannabis regulation outside the “western” world

Parallel session – main hall

Regional rules, implementation, outputs

Chair:

Pavel Bem (Global Drug Commission)
Steph Sherer (ASA and IMCPC)

Speakers:

Representatives of the National Medical Cannabis Agencies of the respective countries


CBD – miracle compound or marketing hype?

Parallel session – hall 1

CBD is sometimes considered “the other miracle cannabinoid”, next to THC. In fact, the only reason why there are so many CBD-related businesses is the legality of the compound – CBD is legal, THC is not. Although CBD has proven to have medical effect, many producers market is as a panacea. Which is a dangerous assumption, from many points of view.

Chair:

Pavel Kubů, MC – (ICCI, KOPAC)

Speakers:

To be specified (free speaker’s slots)


Translational research of cannabinoids: how to get the medicine out fast

Parallel session, hall 2

From preclinical studies to possible clinical use, the translational research utilizes interdisciplinary interactions to maximize the impact of using cannabinoids in both prevention and therapy.

Chair:

Alexandra Šulcová (Medical Faculty, Masaryk University in Brno)

Speakers:

Research Group of Experimental and Applied Neuropsychopharmacology in the Central European Institute of Technology, Masaryk University


17.00-17.30             Coffee break

17.30-18.30

Global regulation systems – review

Plenary session – Main hall, screening to halls 1 and 2

What regulation, what aims, what results, what recommendations – reporting from the parallel sessions

Chair:
  • Michel Kazatchkine (member of the Global Commission on Drug Policy, and United Nations Secretary-General’s Special Envoy for AIDS in Eastern Europe and Central Asia)
  • Jindřich Vobořil (National Drug Coordinator of the Czech Republic (aka “Czech drug czar”)
Speakers:
  • Ingo Ilja Michels (former Head of Unit of the Ministry of Health, Germany)
  • Brendan Hughes (EMCDDA)
  • Nicola Singleton (EMCDDA)
  • Pavel Bém (Global Commission for Drug Policy)
  • Steph Sherer (Americans for Safe Access, and International Medical Cannabis Patients Consortium)
  • Mark Ware (McGill University, and chair of the International Association for Cannabinoids Medicines)

18.30-19.30             Coffee break

19.30-late

Is EU a pasture for medical cannabis cash cows?

Working dinner arrangement / restaurant, lobby / special paid entrance

With unclaimed stakes in the cannabis territory and huge profit margins, there has never been a better time to invest.

  • The booming business. Camparison of the numbers between US and EU. Higher GDP, more citizens, higher number of patients. No central law authority, which should eventually prohibit selling medical cannabis under regional laws.
  • The US experience in the EU – can it be repeated? The synergy between US experience and sources (personal, material) and EU practice (excellent local knowledge), network of contacts of suppliers, clients and general public.
  • Germany example. The biggest and leading European country will have legal cannabis from 2018, covered fully by insurance companies. The amount of cannabis needed will be huge. Where will they get it? What are the implications for other EU and US businesses?
  • Investor’s paradise. The returns of investment in the cannabis business are tremendous, and investors are already lining up to claim the best stakes.
  • EU market benefits: market size, legal stability, synergies and high returns
Presentation:
  • Ben Bronfman (Discorides Global Holdings)
  • TBD